Pfenex, Inc. is a development and licensing Biotechnology Company, which focuses on leveraging its Pfenex Expression Technology platform for developing and improving protein therapies. Its products include PF708, PF743, PF745, CRM197, PF810, PF753 and PFXX. The company was founded on November 19, 2009 and is headquartered in San Diego, CA.
Company profile
Ticker
PFNX
Exchange
Website
CEO
Evert B. Schimmelpennink
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
PFNX stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
5 Oct 20
EFFECT
Notice of effectiveness
5 Oct 20
EFFECT
Notice of effectiveness
5 Oct 20
25-NSE
Exchange delisting
1 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Oct 20
Latest ownership filings
SC 13G/A
BLAIR WILLIAM & CO/IL
11 Feb 21
SC 13G/A
PRIMECAP MANAGEMENT CO/CA/
9 Dec 20
SC 13G/A
FRANKLIN RESOURCES INC
9 Oct 20
SC 13G/A
Weiss Asset Management LP
9 Oct 20
SC 13G/A
Weiss Asset Management LP
9 Oct 20
SC 13G/A
BlackRock Inc.
9 Oct 20
3
Initial statement of insider ownership
9 Oct 20
4
PHILLIP M SCHNEIDER
5 Oct 20
4
Patrick K. Lucy
5 Oct 20
4
Magda Marquet
5 Oct 20
Financial summary
Quarter (USD) | Jun 20 | Mar 20 | Sep 19 | Jun 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 61.24 mm | 61.24 mm | 61.24 mm | 61.24 mm | 61.24 mm | 61.24 mm |
Cash burn (monthly) | 1.52 mm | (no burn) | 3.44 mm | 2.10 mm | 1.78 mm | 2.21 mm |
Cash used (since last report) | 69.79 mm | n/a | 157.88 mm | 96.08 mm | 81.41 mm | 101.44 mm |
Cash remaining | -8.55 mm | n/a | -96.64 mm | -34.84 mm | -20.17 mm | -40.20 mm |
Runway (months of cash) | -5.6 | n/a | -28.1 | -16.6 | -11.4 | -18.2 |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|